ChiCTR2100048428 版本V1.3 版本创建时间2021/07/07 21:54:58 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100048428 

最近更新日期:

Date of Last Refreshed on:

2021-07-07 21:49:33 

注册时间:

Date of Registration:

2021-07-06 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

前列腺穿刺活检效果及影响因素多中心研究

Public title:

A multicenter study on the effect and influencing factors of prostate biopsy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

前列腺穿刺活检效果及影响因素多中心研究

Scientific title:

A multicenter study on the effect and influencing factors of prostate biopsy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈锐 

研究负责人:

陈锐 

Applicant:

Chen Rui 

Study leader:

Chen Rui 

申请注册联系人电话:

Applicant telephone:

+86 13764301103

研究负责人电话:

Study leader's
telephone:

+86 13764301103

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

drchenrui@foxmail.com

研究负责人电子邮件:

Study leader's E-mail:

drchenrui@foxmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市长海路168号

研究负责人通讯地址:

上海市长海路168号

Applicant address:

168 Changhai Road, Yangpu District, Shanghai, China

Study leader's address:

上海市杨浦区长海路168号

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

海军军医大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Naval Medical University

研究负责人所在单位:

海军军医大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Naval Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CHEC2021-092

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海长海医院伦理委员会

Name of the ethic committee:

Shanghai Changhai Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2021-07-05 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

海军军医大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Naval Medical University

研究实施负责(组长)单位地址:

上海市长海路168号

Primary sponsor's address:

168 Changhai Road, Yangpu District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

海军军医大学第一附属医院

具体地址:

上海市长海路168号

Institution
hospital:

The First Affiliated Hospital of Naval Medical University

Address:

168 Changhai Road

经费或物资来源:

自主筹集

Source(s) of funding:

Self-raising

研究疾病:

前列腺癌  

Target disease:

Prostate cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

了解目前开展前列腺穿刺的临床现状、前列腺穿刺活检效果、前列腺特异性抗原等影响因素与前列腺穿刺活检结果的关系,以及多中心之间前列腺穿刺效果的差异,前列腺特异性抗原等影响因素与前列腺穿刺活检结果的关系。  

Objectives of Study:

To determine the current clinical status of prostate biopsy, the effect of prostate biopsy, the relationship between prostate specific antigen and other influencing factors and the results of prostate biopsy, as well as the differences in the effectiveness of prostate biopsy between multiple centers, prostate specific antigen and other influencing factors and prostate puncture The relationship between biopsy results.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

-年龄>18岁
-病理结果为前列腺癌。

Inclusion criteria

- Aged >18 years old;
- The pathological result is prostate cancer.

排除标准:

No

Exclusion criteria:

No

研究实施时间:

Study execute time:

From 2011-01-01 00:00:00 To 2013-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2011-01-01 00:00:00 To 2013-12-31 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

13904

Group:

Case series

Sample size:

干预措施:

Nil

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

海军军医大学第一附属医院 

单位级别:

三级甲等医院 

Institution
hospital:

The First Affiliated Hospital of Naval Medical University

Level of the institution:

Tertiary A Hospital

国家:

美国

省(直辖市):

纽约 

市(区县):

 

Country:

USA

Province:

New York

City:

单位(医院):

纪念斯隆-凯特琳癌症中心 

单位级别:

三级甲等 

Institution
hospital:

Memorial Sloan-Kettering Cancer Center

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学瑞金医院 

单位级别:

三级甲等医院 

Institution
hospital:

Renji Hospital of Shanghai Jiao Tong University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学第一附属医院 

单位级别:

三级甲等医院 

Institution
hospital:

First Affiliated Hospital, School of Medicine of Zhejiang University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第一医院 

单位级别:

三级甲等医院 

Institution
hospital:

Peking University First Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

西安交通大学第一附属医院 

单位级别:

三级甲等医院 

Institution
hospital:

The First Affiliated Hospital of Xi'an Jiaotong University

Level of the institution:

Third-class hospital

测量指标:

Outcomes:

指标中文名:

前列腺特异性抗原

指标类型:

主要指标

Outcome:

PSA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 63 years
最大 Max age 75 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Resman 平台共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Resman

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据收集利用病例报告表来完成。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is mainly collected through thepathology report form.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-07-06 18:52:18